Collagen Solutions Share Discussion Threads

[interstellar] 06/12/2017 08:50

Continues to disappoint/ only people getting fat on this crock of sh#t are the execs

[walbrock82] 05/12/2017 16:25

Management expects to increase sales by 5 times when 2021 comes around and today result didn’t help their cause. The fall in revenue came from lower sales in North America and Asia.

The first six-month saw losses grew to £1.38m, the expectation of a higher revenue didn’t materialise.

Crucially, they have enough financing in place with Cash and cash equivalent at £6.74m. But, the company didn’t allude to net funds dropping from £7.07m to £3.8m in six months. Mostly due to increases in debt.

Collagen paid deferred consideration of £1m to NZ based Southern Lights Biomaterials (an acquisition made in 2014) by drawing down a £1m bond with an interest rate of 10%. Bad news and lack of confidences from lenders.

To understand 7 things Collagen Solutions, click

[fillipe] 22/11/2017 11:46

I'm not sure if the medics have much faith in some of the concepts.

f

[pugugly] 27/10/2017 08:10

fillipe - Agreed - Interesting and needed product - provided if performs as promised but going nowhere fast - Marked down 1st thing and what appear to be significant sells coming through -

[fillipe] 26/10/2017 18:16

Hi Pug, you're welcome.
I'm not in here, but keep a watch. I had COS early 2016 for a small gain, but then lost out later that year on a re-buy.
It's their forever losing the precious £££; which I couldn't take, even for a pharma it gets tiring.

There's great talking the talk there, but it must be wearing a bit thin, although the words of future success seem to slip along with ease.

I'll keep watching for now as I think you are correct about future falls .....some of the past subscribers must be well cheesed off.

Dec 5 for the int's seems light years away.

gl and all best,

g

[pugugly] 26/10/2017 17:02

fillipe: Thansk for heads up Could be further falls tomorrow then.

[interstellar] 26/10/2017 17:01

Disappointing sales. Heard this excuse about delays in customer's projects before and quite unacceptable after the first such occurence. Budget should reflect these probabilities/ possibilities since they seem to be a recurring theme. Need more irons in the fire to compensate. Getting mighty fed up waiting for this lot to perform

[fillipe] 26/10/2017 16:26

Downgraded to Sell sign raised by Hot Stock Rockets, today.

f

[pugugly] 26/10/2017 16:19

Looking very soggy Sales volume building towards close - Not a GSK but share price action similar !!

[tomps2] 28/9/2017 14:34

Investor presentation by Collagen Solutions CEO Jamal Rushdy
at the Hardman & Co’s Investors Forum 20th September 2017.



Collagen Solutions develops, manufactures and supplies medical grade collagen biomaterials for use in research, medical devices, and regenerative medicine.

Introduction – 00:20
Regenerative medicine – 00:44
What Collagen Solutions do: 2:17
How will Collagen Solutions Grow? – 4:12
About collagen and tissue biomaterials – 7:00
Growing the core biomaterials business – 8:32
The competition – 12:00
Collagen Solution’s USP – 13:05
Proprietary products pipeline – 15:04
Financial Highlights – 18:36
Growth & investor proposition – 19:00
Q&A
Knee surgery recovery – 19:45
The regulatory process – 20:28
Demand & supply of collagen – 21:41
Why bovine tissue? & immune reaction? – 22:50

[jacobjohn7] 25/9/2017 09:52

Thanks tim. CE mark nailed on. Timescale after operation study and stats no one in the world can match. Very happy to watch this one build... whilst being invested, I bought a portion slightly higher like others, but I've also averaged down considerably. DYOR

[timbo003] 22/9/2017 01:23

Collagen Solutions were at the Hardman Conference last night, Jamal had a 20 min slot followed by Q&As, he talked about this extended trial and was emphasising its importance, a couple of the Q&As at the end were on the extended study too. It was recorded on video, so it should be available on the Hardman web site shortly, there is also a new Hardman research report updated to reflect recent progress on their web site too

[1toad] 21/9/2017 18:32

Glad you said that inter I feel exactly the same. I bought at 7p but my waiting has turned me into a skeleton.

[interstellar] 21/9/2017 08:30

I admire such consistent and patient enthusiasm. I am 60% down on my investment and i'm getting a bit tired of these jam tomorrow announcements and still the share price goes nowhere.

[18bt] 21/9/2017 08:08

Positive announcement again this morning. If they can get CE mark, that's a large market for them to aim at.

[jacobjohn7] 30/8/2017 20:36

anyone get any titbits from agm?

[jacobjohn7] 23/8/2017 14:08

Any thoughts on timings etc for the CE mark etc? They could be waiting to make an impact at the AGM?

[jacobjohn7] 28/7/2017 09:17

you mean figures wise dan?
When the inhouse products get approval and release we will move.

[timbo003] 26/7/2017 21:15

Link to Hardman report (dated July 25th 2017) referred to above:

[danieldruff2] 26/7/2017 11:16

The report from Hardman was slightly less positive than their previous report of 2 months earlier

[jacobjohn7] 25/7/2017 11:44

Read the report, and all seems well, obviously there are several intangibles at this stage, that if all come to fruition, could make this a very big company!

[jacobjohn7] 25/7/2017 11:42

Collagen Solutions PLC Director/PDMR Shareholding

25/07/2017 11:36am
UK Regulatory (RNS & others)

Collagen Sol (LSE:COS)
Intraday Stock Chart
Today : Tuesday 25 July 2017

Click Here for more Collagen Sol Charts.
TIDMCOS

RNS Number : 0283M

Collagen Solutions PLC

25 July 2017

This announcement contains inside information

Collagen Solutions Plc

(the "Company")

Director/PDMR Dealing

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it was notified today that David Evans, Chairman of the Company, has purchased 900,000 ordinary shares in the Company ("Ordinary Shares") at 5.1 pence per Ordinary Share.

Following the transaction, David Evans' total beneficial holding in the Company has increased to 39,394,554 Ordinary Shares representing 12.15 per cent. of the issued ordinary share capital of the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

[timbo003] 12/7/2017 08:00

New Interview (and article) on Proactiveinvestor:

[slartybartfaster] 07/7/2017 12:53

Jamal Rushdy, CEO of Collagen Solutions said: "We are excited to begin the clinical assessment of long-term scaffold performance in patients who received the ChondroMimetic® implant. To our knowledge, ChondroMimetic® will be the only known, 'unpartnered' product with such long-term clinical evidence, significantly differentiating it from competing therapies. This extension study represents a critical step forward in our ChondroMimetic® development programme, which has the potential to address 450,000 annual cartilage procedures and provide access to a US $500M-$1B market opportunity via a novel, proprietary technology."

There looks to be a very big market in the america alone.